Return-Path: mail.xizpvlivirmavods@email.marcusevansonline.com
Received: from zimbra.bph.cxn (LHLO zimbra.chemaxon.com) (10.128.128.30) by
 zimbra.bph.cxn with LMTP; Tue, 7 Oct 2014 17:44:24 +0200 (CEST)
Received: from localhost (localhost.localdomain [127.0.0.1])
	by zimbra.chemaxon.com (Postfix) with ESMTP id 942CB19F8467
	for <___@___.tld>; Tue,  7 Oct 2014 17:44:24 +0200 (CEST)
X-Virus-Scanned: amavisd-new at zimbra.bph.cxn
X-Spam-Flag: NO
X-Spam-Score: -1.918
X-Spam-Level:
X-Spam-Status: No, score=-1.918 tagged_above=-10 required=6.6
	tests=[BAYES_00=-1.9, DKIM_SIGNED=0.1, DKIM_VALID=-0.1,
	HTML_MESSAGE=0.001, LOTS_OF_MONEY=0.001, RCVD_IN_DNSWL_BLOCKED=0.001,
	RCVD_IN_MSPIKE_H3=-0.01, RCVD_IN_MSPIKE_WL=-0.01,
	SPF_HELO_PASS=-0.001, SPF_PASS=-0.001, URIBL_BLOCKED=0.001]
	autolearn=ham
Authentication-Results: zimbra.bph.cxn (amavisd-new); dkim=pass (1024-bit key)
	header.d=msgfocus.com
Received: from zimbra.chemaxon.com ([127.0.0.1])
	by localhost (zimbra.bph.cxn [127.0.0.1]) (amavisd-new, port 10024)
	with ESMTP id kRA0nQGv_D5t; Tue,  7 Oct 2014 17:44:20 +0200 (CEST)
Received: from relay-8-233.msgfocus.com (relay-8-233.msgfocus.com [46.236.37.233])
	by zimbra.chemaxon.com (Postfix) with ESMTP id 490EA19F845A
	for <___@___.tld>; Tue,  7 Oct 2014 17:44:20 +0200 (CEST)
DKIM-Signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=msgf; d=msgfocus.com;
 h=Content-Type:MIME-Version:X-Mailer:Subject:Date:Reply-To:Message-ID:To:From;
 bh=6KUVQiybcnV0ZWTHEqGZepRChpY=;
 b=6bNd4xsiAMspd8laNDLSvOhhvbcfaW2JphbPe32NgX0fxsQZOFruY3oB5gwfmnc/tL2fGgXT8a0X
   u//+Q/YamWywaWP9EgBEv/IGeyTi3c4EMcygx2p+bUEyqSTFSQVXlv9PtWtuZpYflZeW+fjucEGs
   OIRa+RR0VC1JB9ULMeQ=
Content-Type: multipart/alternative; boundary="----------=_1412696659-55960-1587"
MIME-Version: 1.0
X-Mailer: MessageFocus Launcher (2.0-dev)
Subject: FW: Can you do work for Sanofi-Aventis, Evolva, Novartis, LEO Pharma, Siena Biotech, Astra Zeneca and others?
Date: Tue, 7 Oct 2014 16:44:19 +0100
Reply-To: Samantha Clinton <summits-info@marcusevanscy.com>
Message-ID: <msg-20141007164419702289-1v0I42K6WwXtoX-943212@msgfocus.com>
To: ___@___.tld
From: Samantha Clinton <summits-info@email.marcusevansonline.com>

This is a MIME Multipart Message generated by MessageFocus Launcher (2.0-dev)

------------=_1412696659-55960-1587
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable

Hi,
Hope you are doing well.
Did you get a chance to review my previous mail?
Please let me know if you would like to discuss the below matter.

Warm Regards,
Samantha
___________________________________________________________________________=
____

Hello,

Your firm has been recommended to us as a specialist in drug development. O=
ur Discovery and Pre-Clinical Group consists of thought leading drug discov=
ery and pre-clinical professionals from large and mid-market pharmaceutical=
 and biotechnology companies like:

=E2=80=A2 Astra Zeneca, Reagents & Assay Development
=E2=80=A2 Evolva, CSO
=E2=80=A2 Gr=C3=BCnenthal, Director Preclinical Research
=E2=80=A2 Johnson & Johnson, Head of Neuroscience Medicinal Chemistry
=E2=80=A2 LEO Pharma, Head of Pre-Clinical Outsourcing
=E2=80=A2 Novartis, Global Head, Autoimmunity, Transplantation & Inflammati=
on
=E2=80=A2 Orion Pharma, VP R&D
=E2=80=A2 Sanofi-Aventis Group, Director Global Sourcing
=E2=80=A2 TES Pharma, MD & Co-founder
=E2=80=A2 Vertex Pharmaceuticals, VP R&D
=E2=80=A2 Zealand Pharma, CSO

Each member of our Discovery and Pre-Clinical Group completes an applicatio=
n, confirming their responsibility for their spending budget and providing =
details on:

> Annual company revenue
> Personal drug discovery budget of a minimum 5 million Euros and over
> Sign-off authority on purchasing decisions
> Current and future outsourcing percentages for drug discovery projects
> Products and services of interest
> Purchasing priorities for the next 6-18 months

We are getting together next March and will be bringing one of the referred=
 service providers to come meet privately with our Discovery and Pre-Clinic=
al group. We wanted to better understand if your firms=E2=80=99 expertise c=
an advise on specified topics within the group.

Please let me know when you would be available to discuss further.

Many thanks,
Samantha
Marketing Manager
(00357) 22 84 93 84

PS: to understand the true value of the Summit view what your peers have to=
 say www.discovery-summit.com/SP_Video

If you wish to unsubscribe, please click on the link below.
Please note this is an automated operation.
http://email.marcusevansonline.com/u/11x9i2VLtFI2SMTU

------------=_1412696659-55960-1587
Content-Type: text/html; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head></head>
<body>
<p><span style=3D"font-family: 'Calibri','sans-serif';">Hi,<br> Hope you ar=
e doing well.<br> Did you get a chance to review my previous mail? <br> Ple=
ase let me know if you would like to discuss the below matter.</span></p>
<p style=3D"margin-bottom: 12.0pt;"><span style=3D"font-family: 'Calibri','=
sans-serif';">Warm Regards,<br> Samantha<br> ______________________________=
_________________________________________________</span></p>
<p><font face=3D"calibri,lucida grande,sans-serif">Hello,</font></p>
<p><font face=3D"calibri,lucida grande,sans-serif">Your firm has been recom=
mended to us as a specialist in drug development. Our Discovery and Pre-Cli=
nical Group consists of thought leading drug discovery and pre-clinical pro=
fessionals from large and mid-market pharmaceutical and biotechnology compa=
nies like:&nbsp;</font></p>
<p><font face=3D"calibri,lucida grande,sans-serif">&bull;&nbsp;<b>Astra Zen=
eca</b>, Reagents &amp; Assay Development</font><br><font face=3D"calibri,l=
ucida grande,sans-serif"> &bull;&nbsp;<b>Evolva</b>, CSO</font><br><font fa=
ce=3D"calibri,lucida grande,sans-serif"> &bull;&nbsp;<b>Gr&uuml;nenthal</b>=
, Director Preclinical Research</font><br><font face=3D"calibri,lucida gran=
de,sans-serif"> &bull;&nbsp;<b>Johnson &amp; Johnson</b>, Head of Neuroscie=
nce Medicinal Chemistry</font><br><font face=3D"calibri,lucida grande,sans-=
serif"> &bull;&nbsp;<b>LEO Pharma</b>, Head of Pre-Clinical Outsourcing</fo=
nt><br><font face=3D"calibri,lucida grande,sans-serif"> &bull;&nbsp;<b>Nova=
rtis</b>, Global Head, Autoimmunity, Transplantation &amp; Inflammation</fo=
nt><br><font face=3D"calibri,lucida grande,sans-serif"> &bull;&nbsp;<b>Orio=
n Pharma</b>, VP R&amp;D</font><br><font face=3D"calibri,lucida grande,sans=
-serif"> &bull;&nbsp;<b>Sanofi-Aventis Group</b>, Director Global Sourcing =
</font><br><font face=3D"calibri,lucida grande,sans-serif"> &bull;&nbsp;<b>=
TES Pharma</b>, MD &amp; Co-founder</font><br><font face=3D"calibri,lucida =
grande,sans-serif"> &bull;&nbsp;<b>Vertex Pharmaceuticals</b>, VP R&amp;D</=
font><br><font face=3D"calibri,lucida grande,sans-serif"> &bull;&nbsp;<b>Ze=
aland Pharma</b>, CSO</font><br><font face=3D"calibri,lucida grande,sans-se=
rif"> &nbsp;</font><br><font face=3D"calibri,lucida grande,sans-serif"> Eac=
h member of our Discovery and Pre-Clinical Group completes an application, =
confirming their responsibility for their spending budget and providing det=
ails on:</font></p>
<p><font face=3D"calibri,lucida grande,sans-serif"><i>&gt; Annual company r=
evenue<br> </i>&gt;&nbsp;<i>Personal drug discovery budget</i> of a minimum=
&nbsp;5 million Euros and over</font><br><font face=3D"calibri,lucida grand=
e,sans-serif"> &gt;&nbsp;<i>Sign-off authority</i> on purchasing decisions<=
/font><br><font face=3D"calibri,lucida grande,sans-serif"> &gt; <i>Current =
and future outsourcing percentages</i> for drug discovery projects</font><b=
r><font face=3D"calibri,lucida grande,sans-serif"> &gt;&nbsp;<i>Products an=
d services of interest<br> </i>&gt;&nbsp;<i>Purchasing priorities</i> for t=
he next 6-18 months</font></p>
<p><font face=3D"calibri,lucida grande,sans-serif">We are getting together =
next March and will be bringing one of the referred service providers to co=
me meet privately with our Discovery and Pre-Clinical group.&nbsp; We wante=
d to better understand if your firms&rsquo; expertise can advise on specifi=
ed topics within the group.</font></p>
<p><font face=3D"calibri,lucida grande,sans-serif">Please let me know when =
you would be available to discuss further.</font></p>
<p><font face=3D"calibri,lucida grande,sans-serif">Many thanks,</font><br><=
font face=3D"calibri,lucida grande,sans-serif"> Samantha</font><br><font fa=
ce=3D"calibri,lucida grande,sans-serif"> Marketing Manager</font><br><font =
face=3D"calibri,lucida grande,sans-serif"> (00357) 22 84 93 84</font></p>
<p><font face=3D"calibri,lucida grande,sans-serif">PS: to understand the tr=
ue value of the Summit view what your peers have to say <b><i><u><a href=3D=
"http://email.marcusevansonline.com/c/1fvjIS5ue0rpxcu2sVNbA2tG">www.discove=
ry-summit.com/SP_Video</a></u></i></b></font></p>
<p>&nbsp;</p>

<div style=3D"background-color:white;color:gray;font-size:9pt;font-family:a=
rial,san-serif;padding:10px 15px;margin:5px;line-height:12pt;">
	If you wish to unsubscribe, please click on the link below.<br>
	Please note this is an automated operation.<br>
	<a href=3D"http://www.adestra.com/?src=3Demail"><img border=3D"0" align=3D=
"right" src=3D"http://hosted.adestra.com/messagefocus/pb.gif" alt=3D"Powere=
d by Adestra" width=3D"118" height=3D"17"></a>
	<a href=3D"http://email.marcusevansonline.com/u/11x9i2VLtFI2SMTU" style=3D=
"color:#003399">http://email.marcusevansonline.com/u/11x9i2VLtFI2SMTU</a>
</div>

<img src=3D"http://email.marcusevansonline.com/t/11x9i2VLtFI2SMTU.png" alt=
=3D"">
<!--[if lt mso 12]><img src=3D"https://t.msgf.net/r/1JUjc7yafc4w7Gh.png?c=
=3D1" alt=3D""><![endif]--><![if gt mso 11]><img src=3D"https://t.msgf.net/=
r/1JUjc7yafc4w7Gh.png" alt=3D""><![endif]>
</body>
</html>

------------=_1412696659-55960-1587--